Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Bamadutide Dose Regimens in Obesity and T2DM
NCT03414736Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jan 2018
- Primary completion
- Oct 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bamadutide in type 2 diabetes mellitus (T2DM) and obesity (3 cohorts), sponsored by Sanofi. Primary endpoint: Frequency of gastrointestinal adverse events at 8 months. Started Jan 2018; status: completed.
02
Drugs
bamadutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03414736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03414736.